Bristol-Myers Squibb

Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
Thu, 12/19/19 - 01:11 pm
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
After big M&A year, will pharma move away from massive deals in 2020?
Fierce Pharma
Mon, 12/16/19 - 10:29 pm
M&A
Sanofi
Merck
AbbVie
Allergan
Bristol-Myers Squibb
Celgene
FTC
Bristol-Myers Placed A Big Bet On Celgene’s Pipeline. Will It Pay Off For Investors?
Motley Fool
Mon, 12/16/19 - 10:41 am
Bristol-Myers Squibb
Celgene
M&A
Revlimid
patents
Bristol-Myers wins $752 million in U.S. patent case against Gilead
Reuters
Fri, 12/13/19 - 09:09 pm
Bristol-Myers Squibb
Gilead Sciences
Kite Pharma
patents
Juno Therapeutics
After Its Celgene Acquisition, Bristol-Myers Squibb's Future Looks Bright
Motley Fool
Thu, 12/12/19 - 05:25 pm
Celgene
M&A
Bristol-Myers Squibb
Vedanta Biosciences initiates first-in-patient study of VE800 in combination with Bristol-Myers Squibb’s Opdivo
Pharmaceutical Business Review
Wed, 12/11/19 - 10:10 am
Vedanta Biosciences
VE800
Bristol-Myers Squibb
Opdivo
cancer
clinical trials
Following Strong Phase III Results, BMS Plans to Seek Approval for AML Candidate CC-486
BioSpace
Tue, 12/10/19 - 11:38 pm
Bristol-Myers Squibb
CC-486
AML
Deal of the Year: Bristol-Myers Squibb buys Celgene
Biopharma Dive
Mon, 12/9/19 - 09:51 am
M&A
Bristol-Myers Squibb
Celgene
Bristol Myers Squibb: A Cash-Generating Machine at a Cheap Price
Motley Fool
Sat, 12/7/19 - 11:52 pm
Bristol-Myers Squibb
Myeloma cell therapies, now in pharma hands, move into spotlight
Biopharma Dive
Sat, 12/7/19 - 11:47 pm
ASH2019
cell therapies
Multiple Myeloma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD
Pharmaceutical Business Review
Thu, 12/5/19 - 10:06 am
Bristol-Myers Squibb
Orencia
graft vs host disease
FDA
breakthrough status
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Pharmaceutical Business Review
Wed, 12/4/19 - 10:34 am
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
myelodysplastic syndromes
The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More
Yahoo/Benzinga
Mon, 12/2/19 - 09:42 am
ASH2019
Roche
Bristol-Myers Squibb
Acadia Pharmaceuticals
Biogen
Cassava Sciences
Alector
GW Pharma
Magenta Therapeutics
Fortress Biotech
Mustang Bio
Bluebird Bio
BMS investors bet big on 3 newly acquired Celgene drugs for cancer and MS
Fierce Pharma
Sun, 11/24/19 - 11:35 pm
Bristol-Myers Squibb
Celgene
M&A
ozanimod
liso-cel
bb2121
Having gobbled up Celgene, the Bristol-Myers CEO ducks questions about his key rival
Stat
Fri, 11/22/19 - 10:00 am
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
Merck
M&A
Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene
Pharmaceutical Business Review
Thu, 11/21/19 - 10:14 am
M&A
Bristol-Myers Squibb
Celgene
Bristol-Myers misses main goal of late-stage skin cancer trial
Yahoo/Reuters
Wed, 11/20/19 - 09:50 am
Bristol-Myers Squibb
clinical trials
Yervoy
Opdivo
advanced melanoma
Pfizer, BMS look to early atrial fibrillation screening for potential Eliquis boost
Fierce Pharma
Sun, 11/17/19 - 08:50 pm
Pfizer
Eliquis
Bristol-Myers Squibb
atrial fibrillation
Bristol-Celgene Merger Leaps FTC Clearance; Deal Set To Close Wednesday
Investors Business Daily
Sat, 11/16/19 - 10:30 pm
Bristol-Myers Squibb
Celgene
FTC
M&A
Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at Bayer
Endpoints
Mon, 11/11/19 - 11:06 am
Bristol-Myers Squibb
Opdivo
liver cancer
Yervoy
FDA

Pages